Next-generation sequencing data revealed that 16 patients had tumor aberrations in DNA-repair genes, including BRCA1, BRCA2, ATM, FANCA, PALB2, HDAC2, and CHEK2. Median duration of olaparib was 12 weeks. This evidence concerns the gene ATM and neoplasm.